![]() |
市場調查報告書
商品編碼
1635558
萊姆病檢測市場:規模、佔有率、監管、報銷及 2036 年各細分市場預測Lyme Disease Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
萊姆病是由伯氏疏螺旋體或不太常見的馬氏疏螺旋體引起的。症狀包括發燒、頭痛、疲勞和一種稱為遊走性紅斑的特徵性皮疹。萊姆病的發展分為三個階段:原發局限性階段、早期播散性階段、晚期播散性階段。
萊姆病檢測可以診斷蜱傳細菌伯氏疏螺旋體感染,該疾病可導致神經系統疾病和關節疾病。診斷萊姆病最可靠的方法是在初次感染後幾週進行血液檢測,此時存在抗體。
本報告對全球萊姆病檢測市場進行了深入分析,包括競爭格局、 SWOT 分析、 2036 年市場預測、區域和國家趨勢。
Lyme Disease Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Lyme Disease is caused by the bacterium Borellia burgdorferi or rarely, Borellia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks.The symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. Lyme Disease occurs in three successive stages: Early localized, Early disseminated, and Late disseminate.
Lyme Disease Tests are carried out to diagnose infections caused by the tick-borne bacterium Borrelia, which can result in neurological and joint disease. For diagnosis of Lyme Disease, blood tests are most reliable when performed a few weeks after the initial infection when antibodies are present.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Lyme Disease Test and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Thermo Fisher Scientific Inc, Revvity Inc, bioMerieux SA, Bio-Rad Laboratories Inc, Qiagen NV, Meridian Bioscience Inc, Immco Diagnostics Inc, DiaSorin SpA, Quidel Corp, Diamedix Corp, ZEUS Scientific Inc, Gold Standard Diagnostics, Inc., Viramed Biotech AG, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -